Dr. Thomas J. LewisDr. Carter on COVID Vaccines
Dr. Michael Carter (MD) is the Chief Medical officer of Health Revival Partners. He is an trained anesthesiologist and hormone expert who has become one of the top functional doctors in the world.
Dr. Carter has undergone extensive training at the A4M, ACIM, and IFM on a variety of key functional topics including:
stem cells
peptides
shock wave
energy medicine
Intracellular infections
glaucoma
Alzheimer's / neurodegeneration
supplement
root-cause medicine
Importantly, Dr. Carter is curious and has done significant self-studies across a wide range of functional and root-cause topics. He is available to you for consults and also offers and unlimited program at $300/hr. Here is a link to order a consult.
https://www.healthrevivalpartners.com/product-page/1-hour-functional-physician-consultation
He is offering any of our subscribers a 40% discount on a 1hr consult (promo code 40). His posted charge is $500/hr but if you apply the 40% discount it is $300/hr. If you have complex and unresolved health issues, Dr. Carter may well have a solution for you.
While we were recording part 4 of our series on "How Not to Die Young" a participant asked about the new vaccines. This was an impromptu discussion not intended to be comprehensive. Here is a link to that 10 minute discussion - well worth your time to watch.
https://youtu.be/so4opDrmRSk
Here are the topics he covered:
Vaccines do not undergo long-term safety testing of regular pharmaceuticals. In general, safety testing only lasts 1 year compared to 5 years for most pharmaceuticals. Thus it's hard to assert that they have a good long-term safety profile.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6907a1.htm
Based on this data it's "ambitious" to think the SARS-CoV-2 vaccine will be any better when it is widely distributed.
Del Bigtree discusses safety studies and what might happen when a drug is introduced without long-term safety studies
There is ample evidence that the SARS-CoV-2 virus elicits an innate response to a larger degree compared to the seasonal flu. In this case, the antibody approach (vaccine) is projected to be less effective compared to the flu. Proof of this is that young children are spared by SARS-CoV-2 compared to the seasonal flu. Young children have, be design, stronger innate immune systems compared to adults because their adaptive systems are immature and developing.
https://journals.physiology.org/doi/full/10.1152/ajplung.00183.2020
The information we are exposed to in the U.S. is incongruent with that being discussed overseas.